PATH vs RNAC
Uipath Inc (PATH) versus Cartesian Therapeutics Inc. (RNAC) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RNAC revenue for 2024-12-31 was $38.9M. Net income was -$77.4M. Revenue was up 49.6% from 2023-12-31 to 2024-12-31. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Not investment advice. Open the PATH and RNAC stock pages for the full models.
Not investment advice.